These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8355725)

  • 1. Chronic immune activation in the eosinophilia-myalgia syndrome.
    McKinley KL; Harati Y; Schneider LW
    Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
    Bodey B; Psenko V; Lipsey AL; Kaiser HE
    Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.
    Arranz O; Ara J; Rodríguez R; Saurina A; Mirapeix E; Darnell A
    J Nephrol; 2000; 13(1):59-64. PubMed ID: 10720216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
    Schmitt WH; Csernok E; Kobayashi S; Klinkenborg A; Reinhold-Keller E; Gross WL
    Arthritis Rheum; 1998 Mar; 41(3):445-52. PubMed ID: 9506572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eosinophil colony stimulating factor (Eo-CSF) activity and soluble interleukin-2 receptor (sIL-2R) in patients with reactive eosinophilia].
    Watanabe K; Enokihara H; Saito K; Furusawa S
    Arerugi; 1995 Nov; 44(11):1317-21. PubMed ID: 8857112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia-myalgia syndrome in Wisconsin.
    Butler JC; Davis JP
    Wis Med J; 1990 Dec; 89(12):687-91. PubMed ID: 2293489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
    Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
    Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Episodic angioedema with eosinophilia: a case associated with T cell activation and cytokine production.
    Putterman C; Barak V; Caraco Y; Neuman T; Shalit M
    Ann Allergy; 1993 Mar; 70(3):243-8. PubMed ID: 8452319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cyclosporine A on serum and urinary soluble interleukin-2 receptor in patients with lupus nephritis.
    Tang Z; Zhang J; Zhang S; Li L
    Chin Med J (Engl); 1997 Sep; 110(9):686-9. PubMed ID: 9642325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness.
    Hatch DL; Goldman LR
    Arch Intern Med; 1993 Oct; 153(20):2368-73. PubMed ID: 8215741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
    Mehta R; Shah G; Adler W; Kittur D
    Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
    Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
    Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.